Savara Analyst Ratings
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Savara Analyst Ratings
Buy Rating Affirmed for Savara on Molbreevi's Commercial Promise and Solid Financial Footing
Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating
Savara Analyst Ratings
Savara Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)
Savara Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)
Savara Analyst Ratings
Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)
Savara Analyst Ratings
Optimistic Buy Rating on Savara Amid Anticipated IMPALA-2 Trial Success
Savara Analyst Ratings
JMP Securities Reiterates Market Outperform on Savara, Maintains $8 Price Target
Savara Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Johnson & Johnson (JNJ) and Lantheus (LNTH)
Optimistic Buy Rating for Savara Based on Molgramostim's Market Potential and Study Outcomes
No Data